Targeting CD133+ laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles

Qi, Xinmeng; Yu, Dan; Jia, Bo; Jin, Can; Liu, Xueshibojie; Zhao, Xue; Zhang, Guangxin

doi:10.1007/s13277-015-4007-9

Cited by 32 publications

(26 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Qi et al targeted laryngeal carcinoma with folic acid-modified MSN. They successfully delivered commonly used chemotherapeutic drugs (paclitaxel, cisplatin, 5-fluoruracil) and siRNA targeting ABCG2, a drug efflux pump involved in multidrug-resistance, to CD133 + positive laryngeal cancer cells in vitro and in vivo [ 46 ]. Before, the group showed a greater reduction in laryngeal tumor size in a mouse model by using cisplatin-loaded and folate-conjugated MSN compared to untargeted MSN [ 19 ].…”

Section: Modifications To Control Cellular Uptake Drug Release Anmentioning

confidence: 99%

Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer

2017

View full text Add to dashboard Cite

Even though cancer treatment has improved over the recent decades, still more specific and effective treatment concepts are mandatory. Surgical removal is not always possible, metastases are challenging and chemo- and radiotherapy can not only have severe side-effects but also resistances may occur. To cope with these challenges more efficient therapies with fewer side-effects are required. One promising approach is the use of drug delivery vehicles. Here, mesoporous silica nanoparticles (MSN) are discussed as biodegradable drug carrier to improve efficacy and reduce side-effects. MSN excellently fulfill the criteria for nanoparticulate carriers: their distinct structure allows high loading capacity and a plethora of surface modifications. MSN synthesis permits fine-tuning of particle and pore sizes. Moreover, drug release can be tailored through various gatekeeper systems which are for example pH-sensitive or redox-sensitive. Furthermore, MSN can either enter tumors passively by the enhanced permeability and retention effect or can be actively targeted by various ligands. PEGylation prolongs circulation time and availability. A huge advantage of MSN is their explicitly low toxic profile in vivo. Yet, clinical translation remains challenging. Overall, mesoporous silica nanoparticles are a promising tool for innovative, more efficient and safer cancer therapies.

show abstract

Section: Modifications To Control Cellular Uptake Drug Release Anmentioning

confidence: 99%

Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer

2017

View full text Add to dashboard Cite

show abstract

“…[23] Mesoporous silica Cisplatin, 5-fluoroucail, paclitaxel siRNA ABCG2 Downregulation of ABCG2 significantly enhanced the drug-induced apoptosis and inhibited Hep-2 (laryngeal) tumour growth in vivo. [24] PLGA Paclitaxel Wedelolactone SOX-2, ABCG2…”

Section: Curcuminmentioning

confidence: 99%

“…For example, Qi et al (2015) loaded NPs with siRNA targeting ABCG2 and a chemotherapeutic (cisplatin, 5-fluoroucail or paclitaxel) for the treatment of CD133+ laryngeal carcinoma. The authors reported that the downregulation of ABCG2 significantly enhanced chemotherapeutic drug-induced apoptosis, leading to superior control of tumour growth [24]. Similarly, co-delivery of wedelolatone (Wdl) and paclitaxel incorporated within PLGA NPs downregulated the ABCG2 and SOX-2 expression, sensitising tumour cells to paclitaxel treatment, and reducing the overall percentage of ALDH+ CSCs in vitro and in solid tumours [25].…”

Section: Nanotherapeutic Approaches To Target Cancer Stem Cellsmentioning

confidence: 99%

Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development

Feng

Byrne

Jamal

et al. 2019

Cancers

View full text Add to dashboard Cite

Hypoxia is one of the most common phenotypes of malignant tumours. Hypoxia leads to the increased activity of hypoxia-inducible factors (HIFs), which regulate the expression of genes controlling a raft of pro-tumour phenotypes. These include maintenance of the cancer stem cell compartment, epithelial-mesenchymal transition (EMT), angiogenesis, immunosuppression, and metabolic reprogramming. Hypoxia can also contribute to the tumour progression in a HIF-independent manner via the activation of a complex signalling network pathway, including JAK-STAT, RhoA/ROCK, NF-κB and PI3/AKT. Recent studies suggest that nanotherapeutics offer a unique opportunity to target the hypoxic microenvironment, enhancing the therapeutic window of conventional therapeutics. In this review, we summarise recent advances in understanding the impact of hypoxia on tumour progression, while outlining possible nanotherapeutic approaches for overcoming hypoxia-mediated resistance.

show abstract

“…But many papers have reported targeting CD133 + cells therapy for other cancers. More recently, Qi et al (2016) loaded chemotherapeutic antitumor drugs and small interfering RNA (siRNA) against CD133 + into mesoporous silica nanoparticles (MSNPs) with thermo/pH-coupling sensitivity and site-specificity. These MSNPs successfully inhibited its growth in vivo in a laryngeal cancer mouse model by eliminating CD133 + cells (Qi et al, 2016).…”

Section: Stem Cell Surface Markers In Renal Cscsmentioning

confidence: 99%

Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells

Yuan

GuiXian

et al. 2016

Front. Pharmacol.

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a common form of urologic tumor that originates from the highly heterogeneous epithelium of renal tubules. Over the last decade, targeting therapies to renal cancer cells have transformed clinical care for RCC. Recently, it was proposed that renal cancer stem cells (CSCs) isolated from renal carcinomas were responsible for driving tumor growth and resistance to conventional chemotherapy and radiotherapy, according to the theory of CSCs; this has provided the rationale for therapies targeting this aggressive cell population. Precise identification of renal CSC populations and the complete cell hierarchy will accurately inform characterization of disease subtypes. This will ultimately contribute to more personalized and targeted therapies. Here, we summarize potential targeting strategies for renal cancer cells and renal CSCs, including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors (mTOR), interleukins, CSC marker inhibitors, bone morphogenetic protein-2, antibody drug conjugates, and nanomedicine. In conclusion, targeting therapies for RCC represent new directions for exploration and clinical investigation and they plant a seed of hope for advanced clinical care.

show abstract

Targeting CD133+ laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles

Cited by 32 publications

References 35 publications

Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer

Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer

Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development

Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells

Contact Info

Product

Resources

About